Figure 3. Relative Risk (RR) of All Neurodegenerative Disease, Alzheimer Disease, and Dementia Outcomes With Aromatase Inhibitors, Raloxifene, and Tamoxifen.

Tamoxifen and the aromatase inhibitors were associated with significantly reduced RRs for all neurodegenerative diseases, Alzheimer disease, dementia, and non-Alzheimer dementia in the hormone-modulating therapy treatment groups. More specifically, the steroidal aromatase inhibitor (exemestane) had a greater association than nonsteroidal aromatase inhibitors (anastrozole and letrozole) with reduced RR of neurodegenerative disease outcomes.